Have you tried any of these sources
The following data was extracted (by RC): first authors name, publication year, study design, participants characteristics [sex, age, body mass index (BMI), and disease status], sample size, duration of intervention, and dose of the supplemented L-carnitine
A similar investigation was conducted in the US over a comparable timeframe, encompassing a larger cohort of diabetic patients
137 The non-necessity of SLC7A11 under physiological conditions and the high expression of SLC7A11 in tumors make SLC7A11 a promising target for cancer therapy (Table 1)
According to the NIAAA, 90% of people in recovery will relapse at least once